Guest Host: Steve Roberts

A new study suggests antidepressants may be no more effective than placebo in all but severe cases of depression. A look at how drug effectiveness is measured and weighed against safety concerns in and beyond the drug approval process.

Guests

  • Dr. William Potter serves on the FDA's Psychopharmacologic Drugs Advisory Committee, vice president for translational neuroscience at Merck Research Laboratories; board-certified psychiatrist
  • Dr. Jerry Avorn Professor of Medicine at Harvard Medical School; Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital; author "Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs"
  • Blair Johnson professor of psychology, University of Connecticut; coauthor on new antidepressant study
  • Gardiner Harris science reporter for "The New York Times"

Related Links

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

What Brexit Means For The U.S.

Tuesday, Jun 28 2016With a now-likely U.K. exit from the EU, America’s relationship with a key intelligence and global trade ally will change. Please join us to discuss what the British vote means for the U.S. economy, the 2016 presidential campaign and global security.

The Fallout From The Brexit Vote

Monday, Jun 27 2016The world reacts to Brexit: European Union leaders plan for Great Britain's departure and investors brace for more uncertainty, as the U.S. considers economic and strategic implications.